Cargando…

Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea

PURPOSE: Few studies have been investigated the in vivo efficacy of generic vancomycin products available outside of the United States. In this study, we aimed to compare the in vivo pharmacokinetics (PK) and pharmacodynamics (PD) of five generic vancomycin products available in Korea with those of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hee Kyung, Choi, Su-Mi, Kang, Gaeun, Park, Kyung-Hwa, Lee, Dong-Gun, Park, Wan-Beom, Rhee, Su-jin, Lee, SeungHwan, Jung, Sook-In, Jang, Hee-Chang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105400/ https://www.ncbi.nlm.nih.gov/pubmed/32233172 http://dx.doi.org/10.3349/ymj.2020.61.4.301

Ejemplares similares

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
por: Nham, Eliel, et al.
Publicado: (2022)

A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
por: Kim, Yun, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
por: Kim, Eunwoo, et al.
Publicado: (2019)

Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin
por: Sunwoo, Jung, et al.
Publicado: (2020)

Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
por: Bae, Sungyeun, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Refractory Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient
por: Jang, Mi-Ok, et al.
Publicado: (2015)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
por: Ruczyński, Jarosław, et al.
Publicado: (2019)

Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling
por: Kim, Yong Kyun, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
por: Na, Joo Young, et al.
Publicado: (2022)

Difference in agr Dysfunction and Reduced Vancomycin Susceptibility between MRSA Bacteremia Involving SCCmec Types IV/IVa and I–III
por: Jang, Hee-Chang, et al.
Publicado: (2012)

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
por: Yang, Eunsol, et al.
Publicado: (2021)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Publisher Correction: Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
por: Ruczyński, Jarosław, et al.
Publicado: (2019)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021)

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
por: Kim, Yu Kyong, et al.
Publicado: (2018)

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

First Successful Puncture, Aspiration, Injection, and Re-Aspiration of Hydatid Cyst in the Liver Presenting with Anaphylactic Shock in Korea
por: Park, Kyung-Hwa, et al.
Publicado: (2009)

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Opioid analgesics are the leading cause of adverse drug reactions in the obstetric population in South Korea
por: Choi, Sae Kyung, et al.
Publicado: (2019)

1495 Resistance of Fluoroquinolone in Orientia tsutsugamushi Due to gyrA Mutation in Scrub typhus
por: CHO, Soo Kyung, et al.
Publicado: (2014)

Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
por: Lee, Soyoung, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen
por: Shin, Dongseong, et al.
Publicado: (2017)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
por: Choi, Yewon, et al.
Publicado: (2018)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
por: Oh, JungJin, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects
por: Jin, Xuanyou, et al.
Publicado: (2020)

Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes
por: Lee, Suhrin, et al.
Publicado: (2020)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014)

395 Impact of vancomycin pharmacokinetic/pharmacodynamic data on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
por: Yoo, Reenar, et al.
Publicado: (2014)

Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Leonard, Steven N.
Publicado: (2012)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
por: Hong, Taegon, et al.
Publicado: (2015)

Reversal of rocuronium‐induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis
por: Ji, Sang‐Hwan, et al.
Publicado: (2022)

Rothia aeria Infective Endocarditis: a First Case in Korea and Literature Review
por: Kim, Uh-Jin, et al.
Publicado: (2014)

Draft Genome Sequences of Vancomycin-Intermediate Staphylococcus aureus Strains in South Korea
por: Kim, Jung Wook, et al.
Publicado: (2016)

Once-Daily Gentamicin Administration for Community-Associated Methicillin Resistant Staphylococcus aureus in an in vitro Pharmacodynamic Model: Preliminary Reports for the Advantages for Optimizing Pharmacodynamic Index
por: Kim, Sun Woo, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a0e300emackhhg7q7jvs31aop7